OverviewSuggest Edit

Trevi Therapeutics is a drug development company focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus. 

TypePublic
Founded2011
HQNew Haven, US
Websitetrevitherapeutics.com

Latest Updates

Employees (est.) (May 2019)18
Revenue (FY, 2018)$14.1 M(+131%)
Share Price (May 2019)$8.9 (-1%)

Key People/Management at Trevi Therapeutics

Jennifer L. Good

Jennifer L. Good

President and CEO
Thomas R. Sciascia

Thomas R. Sciascia

Chief Medical Officer
Show more

Trevi Therapeutics Office Locations

Trevi Therapeutics has an office in New Haven
New Haven, US (HQ)
195 Church St
Show all (1)

Trevi Therapeutics Financials and Metrics

Trevi Therapeutics Revenue

Trevi Therapeutics's revenue was reported to be $14.07 m in FY, 2018 which is a 130.9% increase from the previous period.
USD

Revenue (FY, 2018)

14.1m

Revenue growth (FY, 2017 - FY, 2018), %

130.9%

Net income (FY, 2018)

(20.5m)

EBIT (FY, 2018)

(18.4m)

Market capitalization (22-May-2019)

158.2m

Closing stock price (22-May-2019)

8.9

Cash (31-Dec-2018)

7.2m
Trevi Therapeutics's current market capitalization is $158.2 m.
USDFY, 2017FY, 2018

Revenue

6.1m14.1m

Revenue growth, %

131%

General and administrative expense

2.1m4.3m

R&D expense

6.1m14.1m
USDFY, 2017FY, 2018

Cash

22.0m7.2m

Prepaid Expenses

93.0k1.4m

Current Assets

22.2m8.8m

PP&E

14.0k149.0k
USDFY, 2017FY, 2018

Net Income

(12.9m)(20.5m)

Depreciation and Amortization

4.0k23.0k

Accounts Payable

92.0k66.0k

Cash From Operating Activities

(8.0m)(18.3m)
USDY, 2018

Revenue/Employee

1.0m

Financial Leverage

-0.1 x
Show all financial metrics

Trevi Therapeutics Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Trevi Therapeutics Limited

Trevi Therapeutics Online and Social Media Presence

Embed Graph

Trevi Therapeutics News and Updates

Trevi Therapeutics Announces Pricing of Initial Public Offering

NEW HAVEN, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the pricing of its initial public…

Trevi Therapeutics to offer 6.7 million shares in planned IPO priced at $14 to $16 each

Trevi Therapeutics set terms for its planned initial public offering on Monday, saying it plans to offer 4.7 million shares priced at $14 to $16 each to raise up to $75.2 million. The biotech, which is focused on developing treatments for neurologically mediated conditions including Parkinson's dise…

Trevi Therapeutics Frequently Asked Questions

  • When was Trevi Therapeutics founded?

    Trevi Therapeutics was founded in 2011.

  • Who are Trevi Therapeutics key executives?

    Trevi Therapeutics's key executives are Jennifer L. Good and Thomas R. Sciascia.

  • How many employees does Trevi Therapeutics have?

    Trevi Therapeutics has 18 employees.

  • What is Trevi Therapeutics revenue?

    Latest Trevi Therapeutics annual revenue is $14.1 m.

  • What is Trevi Therapeutics revenue per employee?

    Latest Trevi Therapeutics revenue per employee is $781.8 k.

  • Who are Trevi Therapeutics competitors?

    Competitors of Trevi Therapeutics include Cyclacel Pharmaceuticals, Cantabio Pharmaceuticals and Moderna Therapeutics.

  • Where is Trevi Therapeutics headquarters?

    Trevi Therapeutics headquarters is located at 195 Church St, New Haven.

  • Where are Trevi Therapeutics offices?

    Trevi Therapeutics has an office in New Haven.

  • How many offices does Trevi Therapeutics have?

    Trevi Therapeutics has 1 office.